CD19 and neoplasm: These researchers demonstrated that this oncolytic antigen-labeling strategy was capable of inducing tumor rejection through the formation of cytotoxic immunological synapses between tumor cells and CD19-redirected CAR-Ts in animal models, thus increasing their survival rate (112).